McCormick & Company, Incorporated Share Price Target ‘$76.72’, now 3.7% Upside Potential

DirectorsTalk Interviews

McCormick & Company, Incorporated with ticker code (MKC) now have 14 analysts in total covering the stock. The consensus rating is pointing to ‘hold’. The range between the high target price and low target price is between $92.00 and $66.00 suggesting an average analyst share price target price of $76.72. (at the time of writing). Given that the stocks previous close was at $74.01 this is indicating there is a potential upside of 3.7%. There is a 50 day moving average of $73.75 and the 200 moving average now moves to $71.12. The company has a market capitalization of 19.93B. The stock price for the company is currently is currently $74.27 USD

The potential market cap would be $20,662,907,419 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 28.35, revenue per share of $24.96 and a 5.01% return on assets.

McCormick & Company, Incorporated is engaged in manufacturing, marketing and distributing spices, seasoning mixes, condiments and other flavorful products to the entire food industry retailers, food manufacturers and foodservice businesses. The Company operates through two business segments: Consumer and Flavor Solutions. In the Consumer segment, it sells its products under the McCormick brand and a variety of brands around the world, including French’s, Frank’s RedHot, Lawry’s Cholula Hot Sauce and Club House, as well as brands, such as Gourmet Garden, OLD BAY, Zatarain’s, Stubb’s, Thai Kitchen, Simply Asia, Ducros, Schwartz, Kamis, DaQiao and La Drogheria. In the Flavor Solutions segment, the Company provides a range of products to multinational food manufacturers and food service customers. Its sales, distribution and production facilities are located in North America, Europe and China, and additional facilities are based in Australia, Central America, Thailand and South Africa.

Share on:

Latest Company News

Genflow Biosciences reports early findings from SIRT6 gene therapy study

Genflow Biosciences reports early findings from its SIRT6 gene therapy study in older dogs, with further monitoring planned over...

Ilika CEO to discuss battery gigafactory development at Barcelona industry forum

Ilika CEO Graeme Purdy is set to speak at the December 2026 Barcelona battery gigafactory forum, bringing the company's...

Investors demand clear returns as AI spending comes under scrutiny

Investors are demanding clearer returns from AI spending as technology shares face pressure, with corporate earnings, data centre investment...

Novo Nordisk deal puts focus on next generation of oral GLP-1 treatments

Novo Nordisk secures rights to Hengrui's investigational HRS-1596 in a potential $2.6bn deal, targeting the development of once-weekly oral...

itim Group targets retail AI market with new platform launch

ITIM Group is targeting the retail AI market with itimAIQ, a new platform designed to automate operations, improve efficiency...

Drax sets date for 2026 Capital Markets Day and trading update

Drax Group will host its Capital Markets Day on 23 November 2026, providing investors and analysts with a management...

    Search